Trial · NCT07895589
Selective Nerve Root Block Versus Sham to Reduce Surgery for Lumbar Disc Herniation
NCT07895589, Not applicable, Not yet recruiting, Karolinska Institutet
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selective Nerve Root Block Versus Sham to Reduce Surgery for Lumbar Disc Herniation. Trials, record NCT07895589. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895589
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selective Nerve Root Block Versus Sham to Reduce Surgery for Lumbar Disc Herniation
- NCT number
- NCT07895589
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 262 participants, estimated
- Lead sponsor
- Karolinska Institutet
- Conditions
- Lumbar Disc Herniation, Lumbar Radiculopathy, Lumbar Disc Herniation With Radiculopathy
- Interventions
- Selective Nerve Root Block, Sham Procedure
- First posted
- 2026-10-26
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants undergoing lumbar disc surgery | Within 12 months after randomisation | Proportion of participants who undergo surgery for the index lumbar disc herniation within 12 months after randomisation. The outcome is recorded for each participant as yes or no. |
| Secondary | Time to lumbar disc surgery | From randomisation to 12 months | Number of days from randomisation to the first surgery for the index lumbar disc herniation. Participants without surgery will be censored at their last follow-up or at 365 days, whichever occurs first. |
| Secondary | Leg pain intensity measured using the Visual Analogue Scale | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | Leg pain intensity measured using a Visual Analogue Scale (VAS) ranging from 0 to 100 mm, with higher scores indicating greater pain. The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Back pain intensity measured using the Visual Analogue Scale | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | Back pain intensity measured using a Visual Analogue Scale (VAS) ranging from 0 to 100 mm, with higher scores indicating greater pain. The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Leg pain intensity measured using the Numeric Rating Scale | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | Leg pain intensity measured using a Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain). The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Back pain intensity measured using the Numeric Rating Scale | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | Back pain intensity measured using a Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain). The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Oswestry Disability Index | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | Disability measured using the Oswestry Disability Index (ODI), version 2.0. Scores range from 0 to 100, with higher scores indicating greater disability. The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Health-related quality of life measured using the EQ-5D-3L index | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | Health-related quality of life measured using the EQ-5D-3L descriptive system and converted to an index using the selected value set. Higher index values indicate better health; 1 represents full health, and negative values represent health states valued below death. The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Self-rated health measured using the EQ-VAS | Baseline; 2 days, 2 weeks, 6 weeks, 3 months and 12 months after randomisation | EQ-VAS, ranging from 0 (worst imaginable health) to 100 (best imaginable health). The prespecified secondary comparison is at 12 months after randomisation. Earlier measurements will be used for descriptive and exploratory analyses. |
| Secondary | Duration of sick leave | From randomisation to 12 months | Duration of sick leave during the follow-up period, recorded in days. |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895589
GET https://conductscience.org/api/trials/v1/NCT07895589/registered?page=2